Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (1-10 of 294) with videos related to

Pageof 30
Sort By:
Cancers|May 27, 2015
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic ImplicationsGeorg Lenz
Blood|May 3, 2014
Waldenstrom macroglobulinemia: genetics dictates clinical courseGeorg Lenz
Blood|June 11, 2016
Novel NF-κB regulator in ABC DLBCLGeorg Lenz
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Novel therapeutic targets in diffuse large B-cell lymphomaGeorg Lenz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Deciphering Ibrutinib Resistance in Chronic Lymphocytic LeukemiaGeorg Lenz
The Lancet. Haematology|May 28, 2021
Anti-CD25 antibody-drug conjugates: improving the delivery of death to lymphoma cells?Norbert Schmitz, Georg Lenz
Hematological Oncology|June 11, 2015
XI. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other?Birgit Burkhardt, Georg Lenz
Nature Clinical Practice. Oncology|November 3, 2005
Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?Georg Lenz, Martin Dreyling
Expert Review of Clinical Pharmacology|October 25, 2019
Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implicationsFabian Frontzek, Georg Lenz
Cell Cycle (Georgetown, Tex.)|October 5, 2013
PI3K/AKT addiction in subsets of diffuse large B-cell lymphomaMatthias Pfeifer, Georg Lenz
Pageof 30

Showing results (1-10 of 294) with videos related to

Sort By:
Pageof 30
Cancers|May 27, 2015
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic ImplicationsGeorg Lenz
Blood|May 3, 2014
Waldenstrom macroglobulinemia: genetics dictates clinical courseGeorg Lenz
Blood|June 11, 2016
Novel NF-κB regulator in ABC DLBCLGeorg Lenz
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Novel therapeutic targets in diffuse large B-cell lymphomaGeorg Lenz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Deciphering Ibrutinib Resistance in Chronic Lymphocytic LeukemiaGeorg Lenz
The Lancet. Haematology|May 28, 2021
Anti-CD25 antibody-drug conjugates: improving the delivery of death to lymphoma cells?Norbert Schmitz, Georg Lenz
Hematological Oncology|June 11, 2015
XI. Management of paediatric and adult non-Hodgkin lymphoma: what lessons can each teach the other?Birgit Burkhardt, Georg Lenz
Nature Clinical Practice. Oncology|November 3, 2005
Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?Georg Lenz, Martin Dreyling
Expert Review of Clinical Pharmacology|October 25, 2019
Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implicationsFabian Frontzek, Georg Lenz
Cell Cycle (Georgetown, Tex.)|October 5, 2013
PI3K/AKT addiction in subsets of diffuse large B-cell lymphomaMatthias Pfeifer, Georg Lenz
Pageof 30